AbbVie Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064
Mailing Address 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064
Phone (847) 932-7900
Fiscal Year End 1231
EIN 320375147
Financial Overview
FY2024
$135.16B
Total Assets
$12.81B
Cash & Equivalents
$6.65
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 4, 2026 | View on SEC |
| 8-K Current report of material events | January 7, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 10-Q Quarterly financial report | November 4, 2025 | View on SEC |
| 8-K Current report of material events | October 31, 2025 | View on SEC |
| 8-K Current report of material events | October 3, 2025 | View on SEC |
| 4 Insider stock transaction report | October 2, 2025 | View on SEC |
| 4 Insider stock transaction report | October 2, 2025 | View on SEC |
Material Events
8-K Other January 7, 2026
High Impact
- AbbVie announced a significant $1.3 billion pre-tax expense in Q4 2025 for acquired IPR&D and milestone payments.
- This expense is expected to reduce reported profits per share by $0.71 for both GAAP and non-GAAP earnings.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.